EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial

Cynthia M Westerhout iD, Wendimagegn Alemayehu iD, Alain Cohen-Solal, Carolyn S P Lam, Justin A Ezekowitz, Stefano Corda, Ciaran J McMullan, Christopher M O'Connor, Paul W Armstrong iD, VICTORIA Study Group

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15416 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Cynthia M Westerhout und 9 weiteren Autor:innen. Beteiligte Einrichtung: Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Benzaldehydes, Heterocyclic Compounds, 2-Ring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer AG, Merck Sharp & Dohme LLC, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heterogeneity in demographics, aetiology, healthcare access and guideline-directed medical therapy (GDMT), and survival bias of patients with heart failure with reduced ejection fraction (HFrEF) is evident from international trials and registries. The current study examines conventional geographic variation in participants' phenotypes, standard of care, clinical outcomes and treatment effects of vericiguat versus placebo within the VICTORIA trial. We then evaluate an alternative approach to assessing the relationship between geographic variation in the efficacy of new therapeutics. Methods and results Characteristics, standard of care and outcomes (time to first HF hospitalization (HFH) or cardiovascular death (CVD), time to first HFH and to CVD) of the 5050 participants from 42 countries and the effect of vericiguat versus placebo were analysed according to five prespecified geographic regions. Further examination of the study treatment effect according to country-level human development index (HDI) was undertaken to evaluate intra-regional variation. Notable inter-region differences existed in participant characteristics, standard of care at randomization and clinical outcomes. There was no modification of vericiguat's treatment benefit across geographic regions for the primary composite endpoint or its components. When examined by HDI, vericiguat's benefit on HFH and the primary composite was retained overall but attenuated as HDI rose (Pinteraction = 0.009, 0.088, respectively). There was no apparent treatment effect modification due to HDI on cardiovascular death (Pinteraction = 0.623).

Conclusions

Geographic variation in the phenotype of patients with HFrEF, standard of care, and clinical outcomes was observed, while there was no intra-regional heterogeneity in vericiguat's treatment effect. However, when considering contextual/systemic measures via country-level HDI, further insights into treatment effect were revealed. Country-level measures may be helpful in the planning of future trials and in the translation of evidence into practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeBenzaldehydesHeterocyclic Compounds, 2-RingHumansMaleFemaleTreatment OutcomeMiddle AgedVictoriaAgedHospitalizationFollow-Up StudiesPyrimidines

Stichwörter der Autor:innen

Congestive heart failureGeographic regionsHeterogeneityVericiguat

Substanzen

vericiguatBenzaldehydesHeterocyclic Compounds, 2-RingPyrimidines

Autor:innen und Institutionen

  • Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
  • Université Paris Cité, INSERM UMR-S 942(MASCOT), Paris, France.
  • AP-HP Nord, Department of Cardiology, Lariboisiere University Hospital, Paris, France.
  • National Heart Centre Singapore and Duke-National University of Singapore, Singapore.
  • Bayer AG, Basel, Switzerland.
  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Cynthia M Westerhout, Wendimagegn Alemayehu, Paul W Armstrong

Förderung

  • Bayer AG
  • Merck Sharp & Dohme LLC
  • Bayer

Zitieren

APA

Westerhout, C. M., Alemayehu, W., Cohen-Solal, A., Lam, C. S. P., Ezekowitz, J. A., Corda, S., McMullan, C. J., O'Connor, C. M., Armstrong, P. W., & VICTORIA Study Group (2025). Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial. ESC Heart Failure. https://doi.org/10.1002/ehf2.15416

Vancouver

Westerhout CM, Alemayehu W, Cohen-Solal A, Lam CSP, Ezekowitz JA, Corda S, et al. Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial. ESC Heart Failure. 2025. doi:10.1002/ehf2.15416

BibTeX
@article{Westerhout2025,
  author = {Westerhout, Cynthia M and Alemayehu, Wendimagegn and Cohen-Solal, Alain and Lam, Carolyn S P and Ezekowitz, Justin A and Corda, Stefano and McMullan, Ciaran J and O'Connor, Christopher M and Armstrong, Paul W and VICTORIA Study Group, VICTORIA Study Group},
  title = {Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15416}
}
Kostenlos starten →